-
European heatwave's unlikely accomplice: an ocean 'cold blob'
-
Lyles enjoying freedom to focus on speed and stuff off the track
-
Japan's progress paying off at World Cup, says Troussier
-
How the British royal family is funded, and where the money goes
-
Dozens of international teams rushing to Venezuela: UN
-
Russia-annexed Crimea declares 'emergency' amid Ukraine strikes
-
Floods kill two in Taiwan as twin storms approach Japan
-
Stocks slide on renewed tech slump, oil prices fall
-
In the heat, Ivorians don't think twice about using aircon
-
EU hits France's Sanofi with flu vaccine antitrust probe
-
Belgium cancels Waterloo battle reenactment due to heat
-
Europe heatwave swamps hospitals, halts parties
-
Mayweather-Pacquiao rematch postponed indefinitely
-
MEXC Reports 142% Volume Surge for MU Futures Following Record Micron Earnings Beat
-
Four injured, flights cancelled in Japan as twin storms approach
-
Serena Williams to face Joint in Wimbledon return after four-year absence
-
Russia pulls team from gymnastics World Cup event over flag row
-
UN says Iran nuclear pledge needs 'very strong' verification
-
New Zealand internal report warns of Chinese military forays in Pacific
-
Mexico's Sheinbaum and Spanish king use World Cup to mend diplomatic rift
-
Mbappe v Haaland as France face Norway in World Cup group decider
-
'Die together': Ukraine's LGBTQ soldiers fighting Russia -- and for their rights
-
European economies suffer from heatwave
-
Wole Soyinka university theatre: a talent factory for Nigeria and beyond
-
Hospitals overwhelmed as Europe heatwave shifts east
-
Climate change to blame for intensity of Europe heatwave: scientists
-
努莎·奧貝爾與迪特馬爾·沃伊德克 波茨坦如何辜負一名重度殘障幼兒
-
Venezuelan mother digs with bare hands for missing son
-
'Very strong' nuclear verification needed in Iran after war: IAEA head
-
Нуша Аубель и Дитмар Войдке: как Потсдам бросает на произвол судьбы малыша с тяжелой формой инвалидности
-
US lose 3-2 to Turkey after last-gasp strike
-
Turkey beat US 3-2 with last-gasp winner
-
Asian stocks suffer fresh rout as rollercoaster week draws to close
-
French teen in Singapore straw-licking case to enter plea
-
Japan coach hopes World Cup success can inspire Asian rivals
-
Red rocks yield coveted minerals in DR Congo
-
'Unbearable': tracking heat in one of New Delhi's poorest areas
-
Sony discontinues Japan sales of robot puppy 'aibo'
-
Sheinbaum and King Felipe VI use World Cup to mend diplomatic rift
-
Tunisia boss Renard has 'no regrets' despite World Cup flop
-
Viral bullying videos test Bhutan's digital transition
-
Asian stocks drop again as rollercoaster week draws to close
-
Venezuela races to search for survivors after quakes kill at least 235
-
Court battle plays out over Wimbledon tennis expansion plan
-
Attack on ship in Hormuz leads UN to halt evacuation plan for trapped sailors
-
List of worst World Cup performances
-
Yoon leads Women's PGA Championship, Korda satisfied with 'solid' start
-
NZ internal report warns of Chinese military forays in Pacific
-
Japan to play Brazil in World Cup knockouts after nervy Sweden draw
-
Dutch march into World Cup knockouts as group winners
Study shows how fast kilos return after ending weight-loss drugs
When people stop taking the new generation of weight-loss drugs they pile back on the kilos four times faster than they would after ending diet and exercise regimes, new research found Thursday.
But this was mostly because they lost so much weight in the first place, according to the British researchers who conducted the largest and most up-to-date review of the subject.
A new generation of appetite-suppressing, injectable drugs called GLP-1 agonists have become immensely popular in the last few years, transforming the treatment for obesity and diabetes in many countries.
They have been found to help people lose between 15-20 percent of their body weight.
"This all appears to be a good news story," said Susan Jebb, a public health nutrition scientist at Oxford university and co-author of a new BMJ study.
However, recent data has suggested that "around half of people discontinue these medications within a year," she told a press conference.
This might be because of common side effects such as nausea or the price -- these drugs can cost over $1,000 a month in the US.
So the researchers reviewed 37 studies looking at ceasing different weight-loss drugs, finding that participants regained around 0.4 kilograms a month.
Six of the clinical trials involved semaglutide -- the ingredient used in Novo Nordisk's brands Ozempic and Wegovy -- and tirzepatide used for Eli Lilly's Mounjaro and Zepbound.
While taking these two drugs, the trial participants lost an average of nearly 15 kilograms.
However after stopping the medication, they regained 10 kilograms within a year, which was the longest follow-up period available for these relatively new drugs.
The researchers projected that the participants would return to their original weight in 18 months.
Measurements of heart health, including blood pressure and cholesterol levels, also returned to their original levels after 1.4 years.
People who were instead put on programmes that included diet and exercise -- but not drugs -- lost significantly less weight. However it took an average of four years for them to regain their lost kilos.
This meant that people taking the drugs regained their weight four times faster.
- 'Starting point, not a cure' -
"Greater weight loss tends to result in faster weight regain," lead study author Sam West of Oxford University explained.
But separate analysis showed that weight gain was "consistently faster after medication, regardless of the amount of weight lost in the first place," he added.
This could be because people who have learned to eat more healthily and exercise more often continue to do so even as they regain weight.
Jebb emphasised that GLP-1 drugs "are a really valuable tool in obesity treatment -- but obesity is a chronic relapsing condition."
"One would expect that these treatments need to be continued for life, just in the same way as blood pressure medication," Jebb said.
If this was the case, it would impact how national health systems judge whether these drugs are cost-effective, the researchers emphasised.
"This new data makes it clear they are a starting point, not a cure," said Garron Dodd, a metabolic neuroscience researcher at the University of Melbourne not involved in the study.
"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.
L.Henrique--PC